非小细胞肺癌靶向治疗药物的研究现状

Research status of targeted agents for the treatment of non-small cell lung cancer

非小细胞肺癌(NSCLC)占肺癌总量的85%以上,而且由于大多数患者在确诊时已处于中晚期,因此临床药物治疗成为非小细胞肺癌治疗的研究重点。从传统药物治疗到现代靶向药物治疗的不断发展,非小细胞肺癌患者的生存期在不断延长,加上个体化治疗理念的引入,非小细胞肺癌的治疗方式正在不断地扩大与更新,为广大非小细胞肺癌患者带来福音。本文主要对近几年治疗非小细胞肺癌的靶向治疗药物进行综述。

Objective Non-small cell lung cancer（NSCLC） occupied the most parts of the lung cancer with more than 85% patients.And the clinical drug therapy had become the key point of the NSCLC in that the most patients of NSCLC were in middle or terminal stage as they are diagnosed.Now,the NSCLC patients can live longer than before with the help of development of targeted agents,besides,the drug therapy methods had enriched by individualized treatment concept.All these methods have brought the great gifts for the non-small cell lung cancer patients.This paper concludes the latest targeted agents for non-small lung cancer patients.